ESC Heart Failure (Dec 2024)
Prognostic impact of beta‐blocker use by N‐terminal pro‐brain natriuretic peptide level in acute heart failure patients
Abstract
Abstract Aims Both patients with heart failure (HF) with reduced ejection fraction (HFrEF) and those with HF with preserved ejection fraction (HFpEF) present with elevated N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) and have multiple comorbidities; consequently, the prognostic effect of NT‐proBNP according to beta‐blocker (BB) use is unknown. Methods This retrospective study evaluated patients admitted for acute HF between January 2012 and December 2017 at Ulsan University Hospital. Clinical, echocardiographic, laboratory and drug prescription data, including BB data, were collected from the hospital database. Information on mortality was collected by reviewing medical records or using national death data. Results Of the 472 patients evaluated, 216 (45.8%) and 256 (54.2%) patients were and were not prescribed BB at discharge, respectively. A total of 224 (47.5%) patients died within a median follow‐up duration of 44 months. The Kaplan–Meier analysis showed reduced all‐cause mortality with BB in HFrEF (ejection fraction ≤ 40%) but not in HFpEF (ejection fraction > 40%). In the multivariate Cox regression analysis, transmitral to tissue Doppler imaging, early diastolic velocity ratio (E/E′), NT‐proBNP and BB use were independent predictors of all‐cause mortality in HFrEF. Meanwhile, haemoglobin and NT‐proBNP levels were independent predictors of HFpEF. The NT‐proBNP cut‐off value for determining all‐cause mortality was set to 4800 pg/mL. Among HFrEF patients with NT‐proBNP < 4800 pg/mL, the survival rate was higher for patients with BB use than those with no BB use (log‐rank P < 0.001). However, in the HFpEF group, the survival rate associated with BB use did not differ according to the NT‐proBNP levels. Both HFrEF and HFpEF patients with NT‐proBNP levels of ≥4800 pg/mL presented with multiple comorbidities, including lower body mass index and haemoglobin levels and higher creatinine levels, NT‐proBNP levels and E/E′. Conclusion In patients with acute HF, BB use is associated with reduced all‐cause mortality in those with HFrEF but not in those with HFpEF. HFrEF patients with NT‐proBNP levels of <4800 pg/mL treated with BB have a higher survival rate than those not treated with BB. However, this benefit is not seen in HFrEF patients with NT‐proBNP levels of ≥4800 pg/mL or in all HFpEF patients, regardless of the NT‐proBNP level. NT‐proBNP levels are elevated in multiple comorbid conditions, and these comorbidities may contribute to the attenuated effects of BB on all‐cause mortality.
Keywords
